Protara Therapeutics, Inc. TARA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
13.67
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$57.4M | — | -$56.5M | $196.4M |
| 2024 | — | -$44.6M | — | -$35.9M | $167.1M |
| 2023 | — | -$40.4M | — | -$37.6M | $68.3M |
| 2022 | — | -$66.0M | — | -$26.6M | $102.1M |
| 2021 | — | -$47.3M | — | -$35.1M | $161.9M |
| 2020 | — | -$34.0M | — | -$24.3M | $199.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| CONKLING WILLIAM | Chief Commercial Officer | 2026-06-02 | Tax withheld | 6,008 | $4.34 |
| Zummo Jacqueline | Chief R&D Officer | 2026-04-08 | Sell | 1,134 | $5.40 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 13.67 (safe)
- Working capital / assets 0.709
- Retained earnings / assets -1.444
- EBIT / assets -0.308
- Equity / liabilities 15.044
Source: SEC EDGAR filings · CIK 0001359931 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.